Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Avenira Limited ( (AU:AEV) ) has issued an update.
Avenira Limited has secured an additional A$8.79 million strategic investment from its largest shareholder, Hebang Biotechnology (Hong Kong) Investment Limited, a subsidiary of Sichuan Hebang Biotechnology Corporation. The placement, priced at A$0.0075 per new share and subject to shareholder and regulatory approvals, underscores Hebang’s continued strategic backing and confidence in Avenira’s core projects.
Proceeds from the capital raising will be directed toward advancing project readiness at the Wonarah Project, ongoing exploration at Jundee South, and general working capital requirements. The company’s board said the funding will help maintain momentum through critical development milestones targeted for 2026, reinforcing Avenira’s capacity to progress toward first ore shipments and strengthen its project execution alongside key stakeholders.
The most recent analyst rating on (AU:AEV) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Avenira Limited stock, see the AU:AEV Stock Forecast page.
More about Avenira Limited
Avenira Limited is an Australian resources company focused on developing the Wonarah phosphate project and conducting exploration at the Jundee South project. The company operates in the mining and minerals sector, targeting phosphate and related commodities that support agricultural and industrial markets, and is listed on the ASX under the ticker AEV.
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$34.07M
For detailed information about AEV stock, go to TipRanks’ Stock Analysis page.